Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation

Craig S. Sauter, Lauren Lechner, Michael Scordo, Junting Zheng, Sean M. Devlin, Stephen E. Fleming, Hugo Castro-Malaspina, Craig H. Moskowitz

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Whether chemosensitivity, as determined by positron emission tomography using fluorine-18-deoxyglucose (FDG-PET), is a requirement for successful allogeneic hematopoietic stem cell transplantation (allo-SCT) has yet to be established. We analyzed 88 patients with B cell non-Hodgkin lymphoma (B-NHL) for event-free (EFS) and overall survival (OS) according to computed tomography (CT) and FDG-PET criteria before uniform nonmyeloablative (NMA) allo-SCT. Patients who were chemosensitive, according to CT criteria, experienced significantly greater EFS (P < .001) and OS (P < .03) compared with those who were chemorefractory at the time of allo-SCT. Of 58 patients within this cohort who were chemosensitive by CT criteria, there was no difference in EFS (P = .85) or OS (P = .96) between FDG-PET-positive (Deauville 4 to 5, n = 24) and FDG-PET-negative (Deauville 1 to 3, n = 34) patients. There was no difference in survival according to age < or ≥ 60 years, prior autologous-stem cell transplantation, allograft characteristics, or histology. FDG-PET adds no prognostic value in chemosensitive B-NHL before NMA-allo-SCT.

Original languageEnglish (US)
Pages (from-to)881-884
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • Allogeneic transplant
  • B cell non-Hodgkin lymphoma
  • Fluorine-18-deoxyglucose-Positron emission tomography (FDG-PET) scan

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this